Compare QDEL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | MNKD |
|---|---|---|
| Founded | 1979 | 1991 |
| Country | United States | United States |
| Employees | N/A | 592 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 877.0M |
| IPO Year | 2022 | 2004 |
| Metric | QDEL | MNKD |
|---|---|---|
| Price | $12.25 | $2.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $28.25 | $8.69 |
| AVG Volume (30 Days) | 2.6M | ★ 3.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $2,730,200,000.00 | $348,966,000.00 |
| Revenue This Year | $3.51 | $35.81 |
| Revenue Next Year | $3.86 | $11.89 |
| P/E Ratio | ★ N/A | $140.00 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $10.86 | $2.23 |
| 52 Week High | $37.24 | $6.51 |
| Indicator | QDEL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 50.40 |
| Support Level | $10.86 | $2.56 |
| Resistance Level | $17.78 | $2.98 |
| Average True Range (ATR) | 0.98 | 0.13 |
| MACD | 0.17 | 0.04 |
| Stochastic Oscillator | 21.15 | 53.85 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.